Please select the eligibility criteria that correspond to the clinical trial below.
Title: Evaluation of the Efficacy of Next Generation Sequencing in Predicting Embryonic Karyotype and Subsequent Pregnancy Outcomes in in Vitro Fertilization Cycles (IVF)
Brief Summary: To evaluate the benefits of using next generation sequencing to assess embryonic aneuploidy. All viable blastocysts will be biopsied and cryopreserved for future transfer. After the final embryo is cryopreserved, patients will be randomized to either the intervention group or the control group. Patients and doctors are blinded to the randomization until study completion. A Double Embryo Transfer (DET) will be performed with either screened or unscreened embryos depending on randomization. A Single Embryo Transfer (SET) may occur in cases where only one embryo is available for transfer.


Options:
A: Inclusion Criteria:

* at least 2 blastocysts suitable for biopsy on day 5 of embryo development remaining after fresh transfer
* willing and able to give informed consent
* infertility as an indication for IVF/ICSI
* first or second IVF/ICSI cycle
* patients willing to accept single embryo transfer
* BMI range 18 to 35 kg/m2

Exclusion Criteria:

* any type of genetic abnormality or family history of genetic abnormality in subject or partner
* any other non-study related preimplantation genetic testing
* three or more clinical miscarriages (recurrent pregnancy loss, RPL)
* recurrent implantation failure (RIF): no positive β-hCG after transfer (fresh IVF/ICSI cycle or frozen) with no less than 6 cleavage stage embryos or no less than 4 blastocysts, all of good quality and of appropriate developmental stage
* severe endometriosis
* abnormal uterine cavity
* cycles requiring surgical sperm recovery procedures, total asthenozoospermia and/or globozoospermia
* treatment involving use of donor oocytes or use of gestational carrier
B: Inclusion Criteria:

* Patient undergoing IVF/CCS (no PGD banking)
* Patient meets ASRM guidelines for Double Embryo Transfer (DET)
* Donor Sperm OK
* AMH ≥ 1.2
* FSH ≤ 12
* BAFC ≥12
* Max 1 prior failed IVF cycle for patients 35-45 years old
* Patient \<35 years old MUST have 1 prior failed IVF cycle

Exclusion Criteria:

* Chronic endometrial insufficiency
* Use of oocyte donor or gestational carriers
* Medical contraindications to Double Embryo Transfer (DET)
* Male Factor (\<100,000 sperm or surgical sperm)
* Communicating hydrosalpinx (on HSG)
* Single gene disorders or sex selection
C: Inclusion Criteria:

* Women with history of primary or secondary infertility undergoing fresh IVF/ ICSI treatment or frozen embryo replacement cycle
* Age \<49

Exclusion Criteria:

* Non- ovulatory cycles
* Absent uterus
* Uterine instrumentation within previous 3 menstrual cycles
* Women in the oocyte donation program
D: Inclusion Criteria:

* Scheduled to undergo in vitro fertilization for treatment of infertility (1st or 2nd "fresh" attempt); subject can have had no more than one prior failed "fresh" IVF cycle
* Couple able to participate in a research project

  * Able to understand study requirements
  * Willing to sign informed consent
  * Able to return for required follow-up
  * Access to telephone
  * Ability to read and write
* Normal uterine cavity evaluation within one year of enrollment

Exclusion Criteria:

* Medical conditions which may complicate treatment
* No plans to undergo embryo transfer
* Medical contraindication to the transfer of more than a single embryo (i.e. congenital uterine anomaly).
* Concurrent participation in any other interventional trial
* Recurrent pregnancy loss
* Known chromosomal abnormality (e.g. translocation)
* Pre-implantation genetic diagnosis requiring blastocyst biopsy

Answer: B